Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Wave Life Sciences Ltd.NASDAQ: WVE

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $38.25M rose 316.9% year over year, ahead of the -31.6% change in trailing-twelve-month revenue. Sequentially, it rose 121.8% from the prior quarter. Over 3 fiscal years it compounded at +127.1% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 15 analysts of $63.63M (+48.9%) for the fiscal year ending Dec 2026, a step up from the -60.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.25M+121.8% QoQ
Last fiscal yearDec 2025
$42.73M-60.5% YoY
LTMMar 2026
$71.8M-31.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+316.9%-14.4%-331.2 pp
1 year-60.5%+48.9%+109.5 pp
3-year CAGR+127.1%+7.4%-119.7 pp
5-year CAGR+53.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
42.73M USD
Year-over-year change
-60.5%
4-year CAGR
+1.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -31.6% is the 6th highest of 9, against a peer median of -15.7%.
  • Over three fiscal years its annual growth of +127.1% compares with a peer median of +23.3%.
WVE Competitors
Revenue for WVE and competitors
Company Period LTM YoY 3-year CAGR
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$4.8B USD+95.1%+53.0%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$2.18B USD-2.2%+33.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$959.76M USD-0.7%+17.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$450.82M USD-45.6%+23.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$71.8M USD-31.6%+127.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$66.09M USD+45.0%+9.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$45.35M USD-66.4%-31.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$32.08M USD-83.2%+145.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 USD——
Peer median (excluding WVE) —-15.7%+23.3%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.